National Hospital Surabaya continues to strengthen its digital healthcare transformation by becoming the first hospital in Indonesia to implement a feature that provides clinical guideline-based recommendations for laboratory test results directly within its mobile application, National Hospital Apps (NH APPS).
This innovation is the result of a collaboration between National Hospital and Mesh Bio, a Singapore-based health technology company. Through this integration, National Hospital introduces DARA® as a Health Intelligence Platform designed to translate complex medical data into clearer, easier-to-understand, and actionable information and recommendations for patients.
With this feature, when patients receive certain laboratory test results that fall outside the normal reference ranges, they will see more than just a red indicator or warning. They can also access explanations based on clinical guidelines, along with supporting recommendations presented in more accessible language.
DARA® was developed by Mesh Bio using recognized clinical guidelines and structured rule-based clinical logic to generate relevant health recommendations. In terms of information security, Mesh Bio also implements an ISO 27001-certified information security management system as part of its commitment to protecting patient data. Furthermore, patient data processed through DARA® is not used to train artificial intelligence (AI) models.
The information provided through DARA® is expected to help patients better understand their laboratory test results while preparing them for more productive and informed discussions with their doctors. This allows patients to take a more active role in understanding and managing their health.
Ang Hoey Tiong, CEO of National Hospital, stated that integrating DARA® is part of the hospital's commitment to delivering technological innovations that provide tangible benefits to patients.
“By integrating DARA® into NH APPS, we aim to provide technology that helps patients understand their laboratory test results more easily. We believe that AI technology should work hand in hand with medical expertise. Therefore, analytical results continue to be verified by laboratory physicians to maintain accuracy and patient trust,” said Ang Hoey Tiong.
Echoing this sentiment, Dr. Andrew Wu, Co-Founder and CEO of Mesh Bio, stated that this collaboration marks an important step toward making clinically evidence-based health information more accessible to the public.
“Our mission is to transform complex health data into meaningful information that addresses patients' needs. Through our collaboration with National Hospital Surabaya, we are bringing evidence-based clinical guidance directly into patients' hands. We hope this innovation will improve health literacy, reduce anxiety, and encourage more collaborative discussions between patients and doctors,” said Dr. Andrew Wu.
In its implementation, DARA® serves as a supporting technology that helps provide interpretations and recommendations based on clinical guidelines. It does not replace doctors in making diagnoses or determining medical decisions. Verification by laboratory physicians remains an essential part of ensuring the quality and reliability of the information received by patients.
Through this innovation, National Hospital continues to strengthen its commitment to delivering smarter, more integrated, and patient-centered healthcare. The integration of DARA® into NH APPS represents a tangible step toward leveraging artificial intelligence technology to improve patients' understanding of health information and support better communication between patients and healthcare professionals.